Dr. Charles Ryan MD
Associate Professor of Medicine, University of California, San Francisco - CC
Member of the Healthcare Council
Council Member Biography
Charles Ryan, MD, is Associate Professor of Medicine in the Division of Hematology and Oncology at the University of California, San Francisco. His focus is on clinical research for prostate cancer includes hormonal therapies, drug development strategies utilizing targeted therapies, as well as angiogenesis inhibitors, chemotherapy, and tumor vaccines. Dr. Ryan has experience in the study of genomic profiles of prostate tumors following androgen deprivation therapy. He has authored numerous publications in the area of prostate cancer and is an investigator on a number of active clinical trials both within the University of California, San Francisco and through national cooperative groups. (This is me - Update Profile)
Employment History
- 2003 - Unspecified
- Associate Professor of Medicine, University of California, San Francisco - CC
GLG NewsSM Analyses by Charles Ryan
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
Phase III Ascentar (NOVC) Study Halted - Ineffective Drug or Faulty Trial Design?
November 8, 2007
Novacea Halts ASCENT-2 Trial in Advanced Prostate Cancer | www.therapeuticsdaily.com
Prior studies had suggested an improvement in survival when calcitriol was added to weekly docetaxel. The premature closure of this study ocurred due to an increased death rate in patients receiving the combination of weekly docetaxel compared to q 21 day docetaxel. Faulty trial design, and not necessarily inactivity of the drug, may be to blame for this. Competing trials in this space include the Docetaxel Plus GVAX phase III (Cell Genesys) and the Docetaxel plus Bevacizumab phase III study (US Cooperative Group/Genentech)
GLG Study Groups with Charles Ryan(?)
| Study Group Name | No. Members |
|---|---|
| Oncologists (US) | 2218 |
| Urologic Oncologists (US) | 151 |
GLG Live Meetings with Charles Ryan(?)
Charles Ryan has not participated in any GLG Live Meetings.
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.